Changes in left ventricular systolic and diastolic function after chemotherapy for breast cancer with doxorubicin
-
Published:2024-01-02
Issue:6
Volume:22
Page:64-73
-
ISSN:2312-3168
-
Container-title:Siberian journal of oncology
-
language:
-
Short-container-title:Sib. onkol. ž.
Author:
Karput I. A.1ORCID, Snezhitskii V. A.1ORCID, Kurbat M. N.1ORCID, Gorustovich V. A.1ORCID, Karpovich Yu. I.1ORCID, Rubinskii A. Yu.2, Smirnova T. A.3, Babenka A. S.4ORCID
Affiliation:
1. Grodno State Medical University 2. Grodno Regional Clinical Cardiological Center 3. Grodno State Medical University;
Grodno University Clinic 4. Belarusian State Medical University
Abstract
Introduction. Detection of the cardiotoxic effect during chemotherapy (CT) for malignant neoplasms is one of the most important tasks of a practicing physician. Purpose: to study changes in left ventricular systolic and diastolic function using echocardiography (EchoCG) during chemotherapy with doxorubicin in patients with primary breast cancer (BC) and to identify potential markers of early cardiotoxicity (CT).Material and Methods. The study included 100 patients with a confirmed diagnosis of breast cancer who were treated at the health care institution “Grodno University Clinic” (Grodno, Belarus).Results. In the study sample, a number of EchoCG parameters were measured before and after chemotherapy in 100 patients with breast cancer. Depending on the choice of the threshold level of relative reduction in global longitudinal strain (GLS) in %, different median values were recorded in the subgroups with and without CT (before and after chemotherapy). Data are presented on the difference in the relative dynamics of EchoCG indicators in % between the subgroups with CT and without CT, which shows how large the differences between the subgroups are in % after the end of chemotherapy. Against the background of the absence of statistically significant differences, trends towards an increase or decrease in indicators were recorded, which can characterize them as potential CT markers.Conclusion. We hypothesize that indexed end-systolic volume, indexed end-diastolic volume, early diastolic peak velocity of lateral mitral annulus motion may be considered as potential CT markers in the subclinical stage along with GLS; if it is impossible to measure a relative decrease in GLS, these indicators collectively may indicate the development of a CT effect at the subclinical stage. When diagnosing a relative decrease in the GLS index by less than 15 %, but by more than 10 %, we propose to consider the indexed end-systolic volume index as a marker of the early CT effect if its increase after the end of chemotherapy is recorded by 10 % or more, respectively.
Publisher
Tomsk Cancer Research Institute
Reference17 articles.
1. Potievskaya V.I., Akhobekov А.А., Bolotina L.V., Koroleva L.А., Kaprin А.D. Cardiovascular complications of antitumor therapy for breast cancer: diagnosis, prevention and treatment. Siberian Journal of Oncology. 2021; 20(5): 138–48. (in Russian). doi: 10.21294/1814-4861-2021-20-5-138-148. 2. Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H.; ESC Scientifc Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–361. doi: 10.1093/eurheartj/ehac244. 3. Plana J.C., Galderisi M., Barac A., Ewer M.S., Ky B., ScherrerCrosbie M., Ganame J., Sebag I.A., Agler D.A., Badano L.P., Banchs J., Cardinale D., Carver J., Cerqueira M., DeCara J.M., Edvardsen T., Flamm S.D., Force T., Griffn B.P., Jerusalem G., Liu J.E., Magalhães A., Marwick T., Sanchez L.Y., Sicari R., Villarraga H.R., Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014; 27(9): 911–39. doi: 10.1016/j.echo.2014.07.012. 4. Curigliano G., Lenihan D., Fradley M., Ganatra S., Barac A., Blaes A., Herrmann J., Porter C., Lyon A.R., Lancellotti P., Patel A., DeCara J., Mitchell J., Harrison E., Moslehi J., Witteles R., Calabro M.G., Orecchia R., de Azambuja E., Zamorano J.L., Krone R., Iakobishvili Z., Carver J., Armenian S., Ky B., Cardinale D., Cipolla C.M., Dent S., Jordan K.; ESMO Guidelines Committee. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020; 31(2): 171–90. doi: 10.1016/j.annonc.2019.10.023. 5. Vitsenya M.V., Ageev F.T., Gilyarov M.Yu., Ovchinnikov A.G., Orlova R.V., Poltavskaya M.G., Sycheva E.A. Practical recommendations for the correction of cardiovascular toxicity of antitumor drug therapy. Malignant Tumours. 2019; 9(3s2): 609–27. (in Russian). doi: 10.18027/2224-5057-2019-9-3s2-609-627.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|